Gene expression profiling can predict pathological complete response (pCR) to anthracycline-based therapy in estrogen- receptor (ER) negative breast cancer (BC) patients

被引：0
|
作者：
Desmedt, C.
Andre, F.
Azambuja, E.
Haibe-Kains, B.
Larsimont, D.
D'Hondt, V.
Di Leo, A.
Piccart, M.
Pusztai, L.
Sotiriou, C.
机构：
[1] Jules Bordet Inst, Brussels, Belgium
[2] Inst Gustave Roussy, Villejuif, France
[3] Prato Hosp, Prato, Italy
[4] MD Anderson, Houston, TX USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2007年 / 25卷 / 18期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
10564
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Gene expression profiling can predict pathological complete response (pCR) to anthracycline-monotherapy in estrogen-receptor (ER) negative breast cancer (BC) patients.
    Desmedt, C.
    Azambuja, E.
    Di Leo, A.
    Larsimont, D.
    Durbecq, V
    Antoine, D.
    Lallemand, F.
    Haibe-Kains, B.
    Cardoso, F.
    Nogaret, J-M
    Fontaine, D.
    Liebens, F.
    Duhem, C.
    Kains, J-P
    Maerevoet, M.
    Richard, V
    Vindevoghel, A.
    Delaloge, S.
    Buyse, M.
    D'Hondt, V
    Piccart, M.
    Sotiriou, C.
    BREAST CANCER RESEARCH AND TREATMENT, 2006, 100 : S131 - S132
  • [2] Tumor-infiltrating lymphocytes predict response to anthracycline-based chemotherapy in estrogen receptor-negative breast cancer
    West, Nathan R.
    Milne, Katy
    Truong, Pauline T.
    Macpherson, Nicol
    Nelson, Brad H.
    Watson, Peter H.
    BREAST CANCER RESEARCH, 2011, 13 (06):
  • [3] Tumor-infiltrating lymphocytes predict response to anthracycline-based chemotherapy in estrogen receptor-negative breast cancer
    Nathan R West
    Katy Milne
    Pauline T Truong
    Nicol Macpherson
    Brad H Nelson
    Peter H Watson
    Breast Cancer Research, 13
  • [4] CD10 expression as a potential predictor of pathological complete response in ER-negative and triple-negative breast cancer patients treated with anthracycline-based neoadjuvant chemotherapy
    Dimitrov, George
    Shousha, Sami
    Troianova, Petranka
    EXPERIMENTAL AND MOLECULAR PATHOLOGY, 2024, 135
  • [5] Clinical and Pathological Features of Breast Cancer Associated with the Pathological Complete Response to Anthracycline-Based Neoadjuvant Chemotherapy
    Keskin, Serkan
    Muslumanoglu, Mahmut
    Saip, Pinar
    Karanlik, Hasan
    Guveli, Murat
    Pehlivan, Esmehan
    Aydogan, Fatma
    Eralp, Yesim
    Aydiner, Adnan
    Yavuz, Ekrem
    Ozmen, Vahit
    Igci, Abdullah
    Topuz, Erkan
    ONCOLOGY, 2011, 81 (01) : 30 - 38
  • [6] Clinical, pathological and gene expression profiling of estrogen receptor discordance in breast cancer
    Wang, Xi
    Bao, Shengnan
    Jiang, Mengping
    Zou, Xian
    Yin, Yongmei
    CLINICAL & TRANSLATIONAL ONCOLOGY, 2025, 27 (01): : 233 - 256
  • [7] Glucocorticoid Receptor Expression Predicts Good Outcome in response to Taxane-Free, Anthracycline-Based Therapy in Triple Negative Breast Cancer
    Elkashif, Ahmed
    Bingham, Victoria
    Haddock, Paula
    Humphries, Matthew P.
    McQuaid, Stephen
    Mullan, Paul B.
    McCarthy, Helen O.
    Buckley, Niamh E.
    JOURNAL OF ONCOLOGY, 2020, 2020
  • [8] Breast Cancer Index (BCI) and prediction of pathological complete response (pCR) to neoadjuvant chemotherapy in estrogen receptor positive (ER plus ) breast cancer
    Spring, Laura
    Zhang, Yi
    Treuner, Kai
    Park, Hannah
    Yuen, Megan
    Moy, Beverly
    Schnabel, Catherine A.
    Andre, Fabrice
    Bardia, Aditya
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [9] Androgen receptor expression can predict benefit of tamoxifen treatment in patients with ER negative breast cancer
    Hilborn, Erik
    Gacic, Jelena
    Fornander, Tommy
    Skog, Lambert
    Nordenskjold, Bo
    Stal, Olle
    Jansson, Agneta
    MOLECULAR CANCER THERAPEUTICS, 2013, 12 (11)
  • [10] EarlyR genomic signature to predict pathological complete response following neoadjuvant anthracycline-taxane chemotherapy in estrogen-receptor positive (ER plus ) breast cancer.
    Buechler, Steven Allen
    Badve, Sunil S.
    Gokmen-Polar, Yesim
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
12345